Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow TSHA by emailGet an email when TSHA pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about TSHA, unsubscribe in one click. Privacy
📣 What TSHA Says Is Next
first half of 2027 · “Topline data from REVEAL pivotal trial 6-month interim analysis and FDA feedback on the BLA submission pathway for TSHA-102 is expected in the first half of 2027 Second Quarter 2026 Financial Highlights Research and Development Expenses: Research and development expenses were $38.6 million for the three months ended June 30, 2026, compared to $20.1 million for the three months ended June 30, 2025.”
Company press release, Aug 11, 2026 · SEC filing
fourth quarter of 2026 · “Completion of BLA-enabling Process Performance Qualification (PPQ) campaign for TSHA-102 is expected in the fourth quarter of 2026”
Company press release, Aug 11, 2026 · SEC filing
second half of 2028 · “Proceeds included full exercise of the underwriters’ option to purchase additional shares; anticipated cash runway extends into the second half of 2028 and through potential BLA approval of TSHA-102.”
Company press release, Aug 11, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full TSHA picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for TSHA and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.